Skip to main content

NUEVAS FUNCIONES DE LA QUINASA DYRK2 SOBRE EL CONTROL DE LA PROLIFERACION Y EL CICLO CELULAR. MODULACION DE LA RUTA DE MAPK/ERK Y SISTEMA UBIQUITINA PROTEOSOMA

PID2021-124314OB-I00

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Call year 2021
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE CORDOBA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2

  • Jiménez-Izquierdo, Rafael
  • Morrugares, Rosario
  • Suanes-Cobos, Lucía
  • Correa-Sáez, Alejandro
  • Garrido-Rodríguez, Martín
  • Cerero-Tejero, Laura
  • Khan, Omar M.
  • Luna, Susana de la
  • Sancho, Rocío
  • Calzado, Marco A.
FBXW7 is a member of the F-box protein family, which functions as the substrate recognition component of the SCF E3 ubiquitin ligase. FBXW7 is a main tumor suppressor due to its ability to control proteasome-mediated degradation of several oncoproteins such as c-Jun, c-Myc, Cyclin E1, mTOR, and Notch1-IC. FBXW7 inactivation in human cancers results from a somatic mutation or downregulation of its protein levels. This work describes a novel regulatory mechanism for FBXW7 dependent on the serine/threonine protein kinase DYRK2. We show that DYRK2 interacts with and phosphorylates FBXW7 resulting in its proteasome-mediated degradation. DYRK2-dependent FBXW7 destabilization is independent of its ubiquitin ligase activity. The functional analysis demonstrates the existence of DYRK2-dependent regulatory mechanisms for key FBXW7 substrates. Finally, we provide evidence indicating that DYRK2-dependent regulation of FBXW7 protein accumulation contributes to cytotoxic effects in response to chemotherapy agents such as Doxorubicin or Paclitaxel in colorectal cancer cell lines and to BET inhibitors in T-cell acute lymphoblastic leukemia cell lines. Altogether, this work reveals a new regulatory axis, DYRK2/FBXW7, which provides an understanding of the role of these two proteins in tumor progression and DNA damage responses., This work was funded by the Spanish Ministerio de Ciencia e Innovación (MICINN, PID2021-124314OB-I00 to MAC and PID2019-107185GB-I00 to SdlL), Junta de Andalucía-Consejería de Conocimiento, Investigación y Universidad (P20_00470 to MAC) and University of Cordoba (1380920-R to MAC) grants. ACS and LCS were supported by an FPU fellowship (FPU18/ 00845 and FPU20/02699, respectively) from the Spanish Ministerio de Educación y Formación Profesional.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Suppression of metastatic organ colonization and antiangiogenic activity of the orally bioavailable lipid raft-targeted alkylphospholipid edelfosine

  • Alonso-Pérez, Verónica
  • Hernández, Vanessa
  • Calzado, Marco A.
  • Vicente-Blázquez, Alba
  • Gajate, Consuelo
  • Soler-Torronteras, Rafael
  • DeCicco-Skinner, Kathleen
  • Sierra, Angels
  • Mollinedo, Faustino
17 p.-8 fig., Metastasis is the leading cause of cancer mortality. Metastatic cancer is notoriously difficult to treat, and it accounts for the majority of cancer-related deaths. The ether lipid edelfosine is the prototype of a family of synthetic antitumor compounds collectively known as alkylphospholipid analogs, and its antitumor activity involves lipid raft reorganization. In this study, we examined the effect of edelfosine on metastatic colonization and angiogenesis. Using non-invasive bioluminescence imaging and histological examination, we found that oral administration of edelfosine in nude mice significantly inhibited the lung and brain colonization of luciferase-expressing 435-Lung-eGFP-CMV/Luc metastatic cells, resulting in prolonged survival. In metastatic 435-Lung and MDA-MB-231 breast cancer cells, we found that edelfosine also inhibited cell adhesion to collagen-I and laminin-I substrates, cell migration in chemotaxis and wound-healing assays, as well as cancer cell invasion. In 435-Lung and other MDA-MB-435-derived sublines with different organotropism, edelfosine induced G2/M cell cycle accumulation and apoptosis in a concentration- and time-dependent manner. Edelfosine also inhibited in vitro angiogenesis in human and mouse endothelial cell tube formation assays. The antimetastatic properties were specific to cancer cells, as edelfosine had no effects on viability in non-cancerous cells. Edelfosine accumulated in membrane rafts and endoplasmic reticulum of cancer cells, and membrane raft-located CD44 was downregulated upon drug treatment. Taken together, this study highlights the potential of edelfosine as an attractive drug to prevent metastatic growth and organ colonization in cancer therapy. The raft-targeted drug edelfosine displays a potent activity against metastatic organ colonization and angiogenesis, two major hallmarks of tumor malignancy., This work was supported by grants PID2020–119656RB-I00 (to FM) and PID2021–124314OB-I00 (to MAC) funded by MCIN/AEI/10.13039/501100011033 from the Spanish Ministry of Science and Innovation (Agencia Estatal de Investigación), as well as by grants from the Spanish Ministry of Science, Innovation and Universities and Ministry of Economy and Competitiveness (SAF2017–89672-R, SAF2014–59716-R, and SAF2008–02251) (to FM), Spanish Ministry of Health and Consumer Affairs, the ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER) – FIS-PI14/00336 and FIS-PI18/00916 (to AS), Generalitat de Catalunya and Fundació Privada Cellex Barcelona (2014 SGR 530) (to AS), Consejería de Salud of the Junta de Andalucía (PI-0246–2013) (to MAC), RD06/0020/1037 and RD12/0036/0065 from Red Temática de Investigación Cooperativa en Cáncer-Instituto de Salud Carlos III (RTICC-ISCIII), cofunded by the EU's European Regional Development Fund – FEDER (to FM), and European Community’s Seventh Framework Program FP7–2007-2013 (grant HEALTH-F2–2011-256986) (to FM). V.A.-P. acknowledges a predoctoral project-based fellowship from the Ministry of Science and Innovation (BES-2009–024462), and a short-term fellowship from the RTICC-ISCIII., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

FBXW7 tumor suppressor regulation by dualspecificity tyrosine-regulated kinase 2

  • Jiménez-Izquierdo, Rafael
  • Morrugares, Rosario
  • Suanes-Cobos, Lucía
  • Correa-Sáez, Alejandro
  • Garrido-Rodríguez, Martín
  • Cerero-Tejero, Laura
  • Khan, Omar M.
  • Luna, Susana de la
  • Sancho, Rocío
  • Calzado, Marco A.
FBXW7 is a member of the F-box protein family, which functions as the substrate recognition component of the SCF E3 ubiquitin ligase. FBXW7 is a main tumor suppressor due to its ability to control proteasome-mediated degradation of several oncoproteins such as c-Jun, c-Myc, Cyclin E1, mTOR, and Notch1-IC. FBXW7 inactivation in human cancers results from a somatic mutation or downregulation of its protein levels. This work describes a novel regulatory mechanism for FBXW7 dependent on the serine/threonine protein kinase DYRK2. We show that DYRK2 interacts with and phosphorylates FBXW7 resulting in its proteasome-mediated degradation. DYRK2-dependent FBXW7 destabilization is independent of its ubiquitin ligase activity. The functional analysis demonstrates the existence of DYRK2-dependent regulatory mechanisms for key FBXW7 substrates. Finally, we provide evidence indicating that DYRK2-dependent regulation of FBXW7 protein accumulation contributes to cytotoxic effects in response to chemotherapy agents such as Doxorubicin or Paclitaxel in colorectal cancer cell lines and to BET inhibitors in T-cell acute lymphoblastic leukemia cell lines. Altogether, this work reveals a new regulatory axis, DYRK2/FBXW7, which provides an understanding of the role of these two proteins in tumor progression and DNA damage responses., This work was funded by the Spanish Ministerio de Ciencia e Innovación (MICINN, PID2021-124314OB-I00 to MAC and PID2019-107185GB-I00 to SdlL), Junta de Andalucía-Consejería de Conocimiento, Investigación y Universidad (P20_00470 to MAC) and University of Cordoba (1380920-R to MAC) grants. ACS and LCS were supported by an FPU fellowship (FPU18/ 00845 and FPU20/02699, respectively) from the Spanish Ministerio de Educación y Formación Profesional.